Renovaro (RENB) Stock Price, News & Analysis

Company Overview

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $0.80 to $0.88
• 50-Day Range: $0.67 to $1.76
• 52-Week Range: $0.40 to $3.38
• Volume: 461,052 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $128.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Renovaro Stock Analysis - MarketRank™

Renovaro scored higher than 22% of companies evaluated by MarketBeat, and ranked 860th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Renovaro.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Renovaro is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Renovaro is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Renovaro has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.90% of the float of Renovaro has been sold short.

Short Interest Ratio / Days to Cover

Renovaro has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Renovaro has recently increased by 8.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Renovaro does not currently pay a dividend.

Dividend Growth

Renovaro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.90% of the float of Renovaro has been sold short.

Short Interest Ratio / Days to Cover

Renovaro has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Renovaro has recently increased by 8.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.91

News Sentiment

Renovaro has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Renovaro this week, compared to 1 article on an average week.

Search Interest

1 people have searched for RENB on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Renovaro insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.72% of the stock of Renovaro is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.41% of the stock of Renovaro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RENB Stock Analysis - Frequently Asked Questions

How have RENB shares performed this year?

Renovaro's stock was trading at $0.8355 at the beginning of 2025. Since then, RENB stock has decreased by 0.3% and is now trading at $0.8330.
View the best growth stocks for 2025 here.

How were Renovaro's earnings last quarter?

Renovaro Inc. (NASDAQ:RENB) posted its earnings results on Wednesday, February, 19th. The company reported ($0.02) EPS for the quarter.

Who are Renovaro's major shareholders?

Renovaro's top institutional investors include Geode Capital Management LLC (1.47%), Northern Trust Corp (0.56%), Charles Schwab Investment Management Inc. (0.23%) and JPMorgan Chase & Co. (0.22%).
View institutional ownership trends.

How do I buy shares of Renovaro?

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Renovaro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Renovaro investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 2/21/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RENB
• CUSIP: N/A
• CIK: 1527728
• Web: www.enochianbio.com
• Phone: 305-918-1980
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-80,650,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.82%
• Return on Assets: -44.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.08
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 158,720,000
• Free Float: 124,244,000
• Market Cap: $134.40 million
• Optionable: Optionable
• Beta: 0.63